Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.
Cue Health Inc. (HLTH) delivers innovative at-home diagnostic solutions through its integrated platform of molecular testing and mobile health technology. This news hub provides investors and stakeholders with essential updates about the company’s financial performance, product developments, and strategic initiatives.
Access timely announcements including quarterly earnings reports, FDA clearances, partnership agreements, and research breakthroughs. Our curated collection ensures you stay informed about HLTH’s advancements in digital health diagnostics without speculative commentary.
Key updates cover regulatory milestones, new test kit approvals, executive leadership changes, and scientific validation studies. Each release maintains focus on verifiable facts about the company’s patented technology and market position.
Bookmark this page for direct access to primary source materials about Cue Health’s progress in transforming personal health monitoring. Check regularly for objective updates on their mobile-integrated diagnostic ecosystem and business developments.
Cue Health has launched the Cue Clinic™ dashboard as a part of BioReference Laboratories offerings, enhancing patient care for healthcare providers in the U.S. The dashboard integrates digital patient care services, supporting test results, virtual care, scheduling, and e-prescriptions. With the Cue Reader, which provides test results in 20 minutes via the Cue Health App, the solution aims to modernize healthcare practices. BioReference's support includes a full-service onboarding process for providers, facilitating efficient in-house laboratory operations.
Cue Health Inc. (Nasdaq: HLTH) partners with Major League Baseball (MLB) as a presenting sponsor for their Friday Night Baseball games on Apple TV+. This partnership enhances Cue's role in MLB's COVID-19 testing program, providing its portable testing solutions. Cue's COVID-19 self-test delivers lab-quality results in 20 minutes and detects all known variants. The initiative aims to ensure player safety and health during the 2022 season, showing MLB's commitment to health protocols. Cue also serves other renowned organizations like Johns Hopkins Medicine and Mayo Clinic.
In its fourth quarter and full year 2021 results, Cue Health Inc. (HLTH) reported a significant revenue increase to $192.5 million, up from $13.3 million in Q4 2020. Full year revenue reached $618.1 million, compared to $23.0 million in 2020. The company achieved a diluted EPS of $0.22 in Q4 2021, improving from a loss of $1.16 per share a year prior. Q1 FY22 revenue guidance is set between $170 million and $180 million. Cue Health ended 2021 with $409.9 million in cash and equivalents.
Cue Health (Nasdaq: HLTH) has been designated as the preferred testing provider for the 2022 McDonald's All American Games, which is set to commence on March 29 in Chicago. The company's COVID-19 test utilizes advanced molecular technology, yielding lab-quality results in about 20 minutes. Cue's test can identify all known COVID-19 variants and is appropriate for both symptomatic and asymptomatic individuals aged 2 and above. Cue has a history of supporting major sports events, enhancing health safety for athletes and staff.
On March 22, 2022, Cue Health (Nasdaq: HLTH) and Albertsons Companies (NYSE: ACI) launched a partnership to provide in-pharmacy COVID-19 testing across approximately 900 pharmacies nationwide. Customers will receive lab-quality test results via email within 20 minutes. Initially piloted in Washington, the program aims to enhance access to diagnostics. Cue's tests, known for their accuracy and convenience, cater to various needs, including travel and workplace testing. The collaboration symbolizes a step towards evolving healthcare diagnostics, emphasizing convenience and rapid results.
Cue Health (Nasdaq: HLTH) has expanded its offerings to Canada by introducing its molecular COVID-19 self-test, providing lab-quality results within 20 minutes. The test utilizes nucleic acid amplification technology, detecting known COVID-19 variants for individuals aged 2 and older, regardless of symptoms. Consumers can access the test through Cue's eCommerce platform. Cue has also received Interim Order authorization from Health Canada for both professional and consumer use, reinforcing its commitment to enhancing public health through innovative diagnostic solutions.
Cue Health (Nasdaq: HLTH) will release its fourth quarter and full-year 2021 financial results on March 29, 2022. A conference call will follow at 1:30 p.m. PT to discuss these results and company highlights. Interested participants can join by calling (888) 708-0136 for domestic or (929) 517-9009 for international access, using conference ID: 2091976. The live webcast will also be available on their website. Cue Health aims to enhance health information accessibility and is noted for its FDA-authorized COVID-19 test.
Cue Health Inc. (Nasdaq: HLTH) announced a collaboration expansion with UPMC Children's Community Pediatrics to distribute its Health Monitoring Systems and COVID-19 tests across more pediatric clinics in Pittsburgh. This initiative aims to enhance testing capabilities for patients and healthcare providers. Cue's COVID-19 test is noted for its accuracy, delivering lab-quality results within 20 minutes and detecting all known variants, including Omicron. The partnership emphasizes Cue's commitment to improving pediatric care in collaboration with UPMC.
Cue Health (Nasdaq: HLTH), a leader in healthcare technology, announced management presentations at two major investor conferences. The Cowen 42nd Annual Health Care Conference will take place on
